Table 1 Baseline imaging parameters and progression probabilities (PP) (mean ± standard deviation)

From: Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma

Parameters

Early surgery

Later surgery

No surgery

rCBV

1.84 ± 0.64 (4)

2.02 ± 0.65 (5)

1.86 ± 0.30 (3)

rCBVmax

3.78 ± 1.14 (4)

3.95 ± 1.47 (5)

3.36 ± 0.82 (3)

MD (× 10−3 mm2/s)

1.19 ± 0.83 (4)

1.23 ± 0.23 (5)

1.41 ± 0.24 (3)

FA

0.16 ± 0.02 (4)

0.14 ± 0.05 (5)

0.13 ± 0.02 (2)

CL

0.06 ± 0.00 (4)

0.05 ± 0.03 (5)

0.08 ± 0.06 (2)

CP

0.09 ± 0.00 (4)

0.07 ± 0.02 (5)

0.07 ± 0.00 (2)

CS

0.85 ± 0.01 (4)

0.87 ± 0.04 (5)

0.83 ± 0.05 (2)

Cho/Cr

0.39 ± 0.03 (3)

0.41 ± 0.01 (2)

 

PP

0.92 ± 0.13 (4)

0.57 ± 0.51 (5)

0.04 ± 0.63 (2)

  1. The number of lesions included in each parameter are indicated in parenthesis